Prognostic Indicators of Survival in Sinonasal Diffuse Large<scp>B‐Cell</scp>Lymphoma: A National Cancer Database Analysis

Brown, Hannah J.; Varelas, Eleni A; Ganti, Ashwin; Papagiannopoulos, Peter; Mark, Michelle E; Kuan, Edward C.; Tajudeen, Bobby A.

doi:10.1002/lary.29864

Cited by 5 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization describes over 60 distinct NHL subtypes, of which 85%-90% arise from mature B lymphocytes and the remainder arise from mature T or natural killer (NKT) lymphocytes. 9,[24][25][26][27] Within the paranasal sinuses and nasal cavity, B-cell lymphomas carry a more favorable diagnosis, whereas NK/T cell lymphomas are traditionally associated with a rapid, deleterious F I G U R E 1 Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow diagram of study selection clinical course. 4 The two most common SN-NHL include diffuse large B-cell lymphoma (DLBCL), followed by extranodal natural killer/T-cell lymphoma, nasal type (ENKTL).…”

Section: Epidemiologymentioning

confidence: 99%

“…32,36 The most common site of involvement within the sinonasal cavity overall is the maxillary sinus, followed by the nasal cavity, and is commonly associated with orbital extension and ocular symptoms. 24,29,31,35,37 The maxillary sinus is the most common primary site in the Caucasian and African-American populations and nasal cavity is most common in the Asian/Pacific Island population. 2,35 Historically known as lethal midline granuloma, sinonasal ENKTL (SN-ENKTL) is the second most common SN-NHL and most frequently involves the nasal cavity.…”

Section: Epidemiologymentioning

confidence: 99%

“…[104][105][106][107] No consensus has been established on the optimal treatment plan for SN-DLBCL, though patients who receive chemoradiation demonstrate improved overall survival relative to patients who receive multiagent chemotherapy or radiation alone. 24,36,[108][109][110] Addition of immunotherapy may further enhance treatment regimens that already include multi-agent chemoradiotherapy with improved progressionfree and overall survival. 24,36,[111][112][113] Immunotherapy, also known as biological therapy, refers to treatment that stimulates the patient's immune system to target malignant cells.…”

Section: Imagingmentioning

confidence: 99%

“…Recent Surveillance, Epidemiology, and End Results (SEER) database studies demonstrated the incidence of sinonasal DLBCL (SN‐DLBCL) to be between 0.06 and 0.10 in 100,000 31,32 . It has a male predilection, occurs most commonly in the sixth to eight decade of life, and affects the Caucasian population more than any other race 24,31,33–35 . Although SN‐DLBCL affects an older population, it has better 1‐, 5‐, and 10‐year OS than SN‐ENKTL, which were reported to be 87.5%, 69.9%, and 51.2%, respectively, with an average OS time of 10.5 years 32,36 .…”

Section: Epidemiologymentioning

confidence: 99%

“…Although SN‐DLBCL affects an older population, it has better 1‐, 5‐, and 10‐year OS than SN‐ENKTL, which were reported to be 87.5%, 69.9%, and 51.2%, respectively, with an average OS time of 10.5 years 32,36 . The most common site of involvement within the sinonasal cavity overall is the maxillary sinus, followed by the nasal cavity, and is commonly associated with orbital extension and ocular symptoms 24,29,31,35,37 . The maxillary sinus is the most common primary site in the Caucasian and African‐American populations and nasal cavity is most common in the Asian/Pacific Island population 2,35 …”

Section: Epidemiologymentioning

confidence: 99%

See 4 more Smart Citations

Sinonasal lymphoma: A primer for otolaryngologists

Bitner

Htun

Wang

et al. 2022

Laryngoscope Investig Oto

Self Cite

View full text Add to dashboard Cite

Objective: Sinonasal lymphomas are a rare entity that commonly present with nonspecific sinonasal symptoms and are often recognized immediately. Through this review, we aim to summarize important principles in diagnosis and treatment of sinonasal lymphomas, with the goal of disseminating the current knowledge of this under-recognized malignancy to otolaryngologists.Methods: Systemic review using PRISMA guidelines of foundational scholarly articles, guidelines, and trials were reviewed focusing on clinical characteristics of key sinonasal lymphoma subtypes, along with available treatments in the otolaryngology, medical oncology, and radiation oncology literature.Results: Sinonasal lymphoma are derived from clonal proliferation of lymphocytes at various stages of differentiation, of which diffuse large B-cell lymphoma (DLBCL) and extranodal natural killer/T-cell lymphoma (ENKTL) are the most common. Diagnosis and staging require biopsy with immunohistochemistry in conjunction with imaging and laboratory studies. Treatment is ever evolving and currently includes multi-agent chemotherapy and/or radiation therapy. Conclusion:Otolaryngologists may be the first to recognize sinonasal lymphoma, which requires a comprehensive workup and a multidisciplinary team for treatment.Symptoms are nonspecific and similar to many sinonasal pathologies, and it is crucial for otolaryngologists to keep a broad differential.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Section: Imagingmentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

See 3 more Smart Citations

Sinonasal lymphoma: A primer for otolaryngologists

Bitner

Htun

Wang

et al. 2022

Laryngoscope Investig Oto

Self Cite

View full text Add to dashboard Cite

show abstract

Primary sinonasal lymphoma: A multi‐institutional experience of clinical presentation, treatment, and outcomes

Eide

Kshirsagar

Birkenbeuel

et al. 2022

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

Background Sinonasal lymphoma (SL) is a heterogeneous, underrecognized neoplastic disorder with limited outcomes data. We sought to better define outcomes by subtype and treatment at 2 referral centers over the past 2 decades. Methods Demographics, clinicopathologic data, and treatment outcomes for patients treated for SL were queried from January 1, 2000 to December 31, 2021 at 2 tertiary academic medical centers. Results Eighty‐four patients were included, with an average age at diagnosis of 63.4 ± 15 years. There were 34 females (40.5%). The majority of patients had an Eastern Cooperative Oncology Group (ECOG) score of <2 (76.2%) and the most common presenting symptom was facial swelling/pain (26.2%). The most common primary site was the nasal cavity (36.9%). Diffuse large B‐cell lymphoma was the most common subtype (46.4%), followed by extranodal NK/T‐cell lymphoma (17.9%). Chemotherapy was the most common treatment strategy (n = 59, 70.2%), followed by radiation therapy (n = 35, 41.7%) and immunotherapy (n = 24, 28.6%). Disease‐specific survival rates at 1, 5, and 10 years were 85.7%, 73.6%, and 58.6%, respectively. Eighteen patients (21.4%) developed recurrence. On multivariate analysis, higher ECOG score (p < 0.0001) and history of head and neck radiation (p = 0.048) were associated with worse survival. Younger age was associated with greater risk of recurrence (p = 0.022) and male sex was associated with more treatment side effects (p = 0.012). Conclusion This is the largest multi‐institutional analysis of SL characteristics and outcomes. Our work suggests that, although disease control in the first 5 years is reasonable, 10‐year outcomes remain challenging. Further studies are needed to investigate new treatment paradigms and risk stratification.

show abstract

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

BackgroundSinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represents a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.MethodsIn accordance with prior ICAR documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.ResultsThe ICNST document consists of 4 major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.ConclusionAs an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.This article is protected by copyright. All rights reserved

show abstract

Prognostic Indicators of Survival in Sinonasal Diffuse LargeB‐CellLymphoma: A National Cancer Database Analysis

Cited by 5 publications

References 32 publications

Sinonasal lymphoma: A primer for otolaryngologists

Sinonasal lymphoma: A primer for otolaryngologists

Primary sinonasal lymphoma: A multi‐institutional experience of clinical presentation, treatment, and outcomes

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Contact Info

Product

Resources

About